Caso contributivo
L’adolescente obeso: è importante valutare i genitali
Obese adolescents: genitals evaluation is important
Benedetta Mainetti1, MariaTeresa Nasi2, Enrico Valletta1
1UO di Pediatria, Ospedale “G.B. Morgagni - L. Pierantoni”, Forlì
2UO di Neurochirurgia, Ospedale “M. Bufalini”, Cesena
AUSL della Romagna
Novembre 2018
Descriviamo il caso di un adolescente con obesità e ritardo puberale nel quale gli accertamenti ormonali e di imaging hanno permesso di diagnosticare un adenoma ipofisario prolattina-secernente. Il trattamento con cabergolina ha determinato la riduzione delle dimensioni del prolattinoma e la ripresa dello sviluppo puberale.
Contenuto riservato
Per leggere l'articolo è necessario effettuare il login.
Classificazione MeSH
Bibliografia
- Hoffmann A, Adelmann S, Lohle K, Claviez A, Müller HL. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur J Pediatr 2018;177(1):125-32.
- Steele CA, MacFarlane IA, Blair J, et al. Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes. Eur J Endocrinol 2010;163(4):515-22.
- Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P. Hyperprolactinemia: different clinical expression in childhood. Horm Res Paediatr 2010;73(3):187-92.
- Eren E, Yapıcı Ş, Çakır ED, Ceylan LA, Sağlam H, Tarım Ö. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol 2011;3(2):65-9.
- Catli G, Abaci A, Altincik A, et al. Hyperprolactinemia in children: clinical features and long-term results. J Pediatr Endocrinol Metab 2012;25(11-12):1123-8.
- Fideleff HL, Boquete HR, Suarez MG, et al. Prolactinoma in children and adolescents. Horm Res 2009;72:197-205.
- Colao A, Loche S, Cappa M, et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83(8):2777-80.
- Guaraldi F, Storr HL, Ghizzoni L, Ghigo E, Savage MO. Paediatric pituitary adenomas: a decade of change. Horm Res Paediatr 2014;81(3):145-55.
- dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 2011;19(4):800-5.
- Schmid C, Goede DL, Hauser RS, et al. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 2006;136(15-16):254-8.
- Galluzzi F, Salti R, Stagi S, La Cauza F, Chiarelli F. Reversible weight gain and prolactin levels - long-term follow-up in childhood. J Pediatr Endocrinol Metab 2005;18(9):921-4.
- Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA 2017;317(5):516-24.
- Auriemma RS, Granieri L, Galdiero M, et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology 2013;98(4):299-310.
- Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85(6):2247-52.
- Thakker RV, Newey PJ, Walls GV, et al; Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012;97(9):2990-3011.
- Vergès B, Bourelle F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002;87(2):457-65.